There is no indication that the Oxford-AstraZeneca Covid-19 vaccine is linked to an increased risk of blood clots, the EU's medicines regulator says.
It said the number of cases in vaccinated people was no higher than in the general population.
The statement came after a number of countries, including Denmark and Norway, suspended the use of the jab.
The suspension followed reports that a small number of people had developed clots after receiving the vaccine.
There were also reports that a 50-year-old man had died in Italy after developing deep vein thrombosis (DVT) following a dose of the jab.
"There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine," the European Medicines Agency (EMA) said on Thursday.
"The vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing," it added.
It said there had been 30 cases of "thromboembolic events" among the five million Europeans who have received the jab.
AstraZeneca said the drug's safety had been studied extensively in clinical trials. "Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine," a spokesperson said.
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) said there was no evidence the vaccine had caused problems, and people should still go and get vaccinated when asked to do so. "Blood clots can occur naturally and are not uncommon. More than 11 million doses of the Covid-19 AstraZeneca vaccine have now been administered across the UK," said Phil Bryan of the MHRA.
The decision to temporarily suspend the use of AstraZeneca's jab has come as a setback for a European vaccination campaign that has stuttered into life, partly due to delays in delivery of the drug.
Which countries are not using the drug?
Denmark, Norway and Iceland have temporarily suspended the rollout of the vaccine. Italy and Austria, meanwhile, have stopped using certain batches of the drug as a precautionary measure.
The suspensions in Italy and Austria involve different batches of the vaccine.
Estonia, Latvia, Lithuania and Luxembourg have also suspended the use of the same batch as Austria.
In an earlier statement, the EMA said Denmark's decision was a "precautionary measure [taken] while a full investigation is ongoing into reports of blood clots in people who received the vaccine, including one case in Denmark where a person died".
Italy's medicines body said its decision was "precautionary", adding that no link had been established between the vaccine and subsequent "serious adverse events".
Two Italians are reported to have died after receiving the vaccine, and an unnamed source told Reuters news agency that their deaths are what prompted the temporary suspension.
Austria, meanwhile, took its decision after a woman died 10 days after vaccination because of "severe blood coagulation problems". The Austrian doses were part of a batch of one million doses, identified as ABV5300, that was sent to 17 European countries.
The EMA said its safety committee was reviewing the Austrian case but made clear that there was "no indication that vaccination has caused these conditions".
No details of the Danish death have been given, but health officials said they were pausing use of the vaccine for 14 days in what Health Minister Magnus Heunicke called a "precautionary measure". Although no link had been established, he said "we must respond in a timely and careful manner" until a conclusion was reached.
Norway's public health institute said it would follow the Danish move to halt all use of the vaccine until the Danish cases were investigated. "We are waiting for more information to see if there is a link between the vaccine and this blood clot case," said Geir Bukholm of the National Institute of Health.
Iceland was also suspending use of the vaccine, the chief epidemiologist told public broadcaster Ruv, to "err on the side of caution".
Later on Thursday, the French government said it would continue to use the AstraZeneca jab. "The benefits... are higher than the risks," Health Minister Olivier Véran said.
How significant are concerns about the Oxford-AstraZeneca drug?
Officials say they have received reports of fatal or life-threatening blood clots in a small number of people who had recently received a dose of the Oxford-AstraZeneca vaccine. That may sound worrying, but it is not yet known if there is any connection between the two things.
A full investigation into batch quality is ongoing, but a defect is considered unlikely.
Overall, 30 cases of thromboembolic events have been reported among the five million people vaccinated with the AstraZeneca vaccine in the European Economic Area.
Any approved treatment, including vaccines, carries a risk of some side effects for some people, but most are usually mild and severe ones are rare.
It's also worth noting that blood clots can occur naturally and are not uncommon. They are believed to cause symptoms in around one in every thousand people in the UK every year.
https://news.google.com/__i/rss/rd/articles/CBMiMGh0dHBzOi8vd3d3LmJiYy5jby51ay9uZXdzL3dvcmxkLWV1cm9wZS01NjM1Nzc2MNIBNGh0dHBzOi8vd3d3LmJiYy5jby51ay9uZXdzL2FtcC93b3JsZC1ldXJvcGUtNTYzNTc3NjA?oc=5
2021-03-11 18:00:21Z
52781429124065
Tidak ada komentar:
Posting Komentar